Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide

Nature Biotechnology

Volumn 18, Issue 7, 2000, Pages 735-739

  Marino, Maria ^a   Ruvo, Menotti ^a   De Falco, Sandro ^a   Fassina, Giorgio ^a  

^a TECNOGEN SCpA   (Italy)

Author keywords

Autoimmune diseases; Combinatorial chemistry; Fc R inhibition; Lupus erythematosus; Multimeric peptide

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; FC RECEPTOR; IMMUNOGLOBULIN BINDING FACTOR; PLACEBO; SINGLE STRANDED DNA; TETRAMER; TRIPEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULONEPHRITIS; IMMUNE COMPLEX DEPOSITION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BINDING; SHEEP ERYTHROCYTE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGE FACTORS; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BIOTINYLATION; COMBINATORIAL CHEMISTRY TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; RECEPTORS, FC; U937 CELLS;

ANIMALIA; OVIS ARIES;

EID: 0033911048     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/77296     Document Type: Article

References (32)

1. O'Dell, J.R. & Kotzin, B.L. Systemic lupus erythematosus. In Samter's immunologic diseases. (eds Frank, M.M., Austen, K.F., Claman, H.N., & Unanue, E. R.) 667-697 (Little, Brown, Boston; 1995).
2. Baccala, R., Quang, T.V., Gilbert, M., Ternyck, T. & Avrameas, S. Two murine natural polyreactive autoantibodies are encoded by non-mutated germ-line genes. Proc. Natl. Acad. Sci USA 86, 4624-4628 (1989).
3. Marion, T.N., Bothwell, A.L.M., Briles, D.E. & Janeway, C.A. IgG anti-DNA autoantobodies within an individual autoimmune mouse are the products of clonal selection. J. Immunol. 142, 4269-4274 (1989).
4. Schett, G. et al. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and-negative sera. Arthritis Rheum. 43, 420-428 (2000).
5. Reichlin, M. Current perspectives on serological reactions in SLE patients. Clin. Exp. Immunol. 44, 1-10 (1981).
6. Franceschini, F. et al. Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. Lupus 8, 215-219 (1999).
7. Mattioli, M. & Rechlin, M. Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Arthritis Rheum. 17, 421-429 (1974).
8. Reichlin, M. et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum. 42, 69-75 (1999).
9. Hasegawa, H. et al. High frequency of antibody activity against ribosomal protein S10 in anti-Sm sera from patients with systemic lupus erythematosus. Lupus 8, 439-443 (1999).
10. Tsao, B.P. et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J. Immunol. 149, 350-358 (1992).
11. Mannik, M. Pathophysiology of circulating immune complexes. Arthritis Rheum. 25, 783-787 (1982).
12. Baumann, U. et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 164, 1065-1070 (2000).
13. Szalai A. J. et al. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol. 164, 463-468 (2000).
14. Jazwinska, E.C., Banyer, J.L., Gatenby, P.A. & Serjeantson, S.W. Fc gamma RII alpha: sequencing of the ligand binding domain in systemic lupus erythematosus patients. Clin. Exp. Immunol. 86, 199-202 (1991).
15. Clynes, R., Dumitru, C. & Ravetch, J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279, 1052-1054 (1998).
16. Ravetch, J.V. & Clynes, R.A. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16, 421-432 (1998).
17. Sylvestre, D.L. & Ravetch, J.V. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265, 1095-1098 (1994).
18. Fassina, G., Verdoliva, A., Odierna, M.R., Ruvo, M. & Cassani, G. Protein A mimetic peptide ligand for affinity purification of antibodies. J. Mol. Recog. 9, 564-569 (1996).
19. Fassina, G., Verdoliva, A., Palombo, G., Ruvo, M. & Cassani, G. Immunoglobulin specificity of TG19318: a novel synthetic ligand for antibody affinity purification. J. Mol. Recog. 11, 128-133 (1998).
20. Burton, D.R., Jefferis, R., Partridge, L.J. & Woof, J.M Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI). Molec. Immunol. 25, 1175-1181 (1988).
21. Lund, J. et al. Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors. FASEB J. 9, 115-119 (1995).
22. Theofilopoulos, A.N. Murine models of lupus. In Systemic lupus erythematosus. (ed. Lahita, R.G.) 121-194 (Churchill Livingstone, New York, NY; 1992).
23. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jekins, N.A. & Nagata, S. Lymphoproliferation disorder in mice explained by effects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
24. Lemay, S., Mao, C. & Singh, A. Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int. 50, 85-93 (1996).
25. Mannik, M., Agodoa, L.Y. & David, K.A. Rearrangement of immune complexes in glomeruli leads to persistence and development of electron dense deposits. J. Exp. Med. 157, 1516-1528 (1983).
26. Gauthier, V.J. & Mannik, M. Only the initial binding of cationic immune complexes to glomerular anionic sites is mediated by charge-charge interactions. J. Immunol. 138, 3266-3271 (1986).
27. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl Acad. Sci. USA 93, 8563-8568 (1996).
28. Baylink, D.J. Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309, 306-308 (1983).
29. Piper, J.M., Ray, W.A., Daugherty, J.R. & Griffin, M.R. Corticosteroid use and peptic ulcer disease: role of non-steroidal anti-inflammatory drugs. Ann. Intern. Med. 114, 735-740 (1991).
30. Pryor, B.D., Bologna, S.G. & Kahl, L.E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 39, 1475-1482 (1996).
31. Hoover, R.G. et al. Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J. Clin. Invest 95, 241-247 (1995).
32. Fearon, D.T. & Wong, W.W. Complement ligand-receptor interactions that mediate biological responses. Annu. Rev. Immunol. 1, 243-271 (1983).